Loading
Fetching the latest research
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN.
Paper source
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
Links back to this Rigor Record.
This rigor review was examined and confirmed by Adcurare Editorial · July 5, 2026
Adcurare assesses methodological rigor, not the importance of the findings. See how we evaluate →
This Adcurare Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
The paper's major strengths are a clear scientific premise, well-reported biological variables, and transparent limitations. The critical weaknesses are the complete absence of a data/code availability statement, inadequate documentation of ethical approvals (unnamed IRB, no consent), and missing key methodological details (no power analysis, no outlier handling, no reporting guideline). The extremely large protective effect reported for ACE inhibitors (OR 0.33) is flagged as implausible by the integrity check, and the proprietary registry data source raises replicability concerns; an informed reader should weigh these issues heavily.
Three independent rigor evaluations were synthesized. All three reviewers converged on most dimensions; the only divergence was on key resources (whether drug class alone is adequate) and statistical analysis (whether missing p-values alone constitutes a warn). I adopted the stricter interpretation for both, resulting in a lower overall score than any single reviewer. The statistics verification component checked only 3 tests (all consistent), but coverage is limited; the result does not confirm overall statistical validity. The integrity block flagged the ACE inhibitor effect size as implausibly large.
12 major claims checked against the paper's own evidence: all adequately supported.
Found 3 reported tests, but none could be recomputed (missing degrees of freedom or sample size).
6 integrity concerns flagged (1 high).
4 copyedit issues flagged: mostly clarity, consistency, punctuation.
This published paper has significant robustness gaps. An informed reader should be cautious: the extremely large protective effect for ACE inhibitors (OR 0.33) is inconsistent with subsequent RCTs and likely driven by uncorrected confounding or data issues; the missing data/code availability prevents independent verification; and the ethics documentation is incomplete. These issues together justify a call for an independent re-analysis or a correction detailing the sensitivity of results to confounding and missing data assumptions.